Biosimilars, close replicas of biologic drugs, are increasingly coming to the fore in the pharmaceutical market. Their regulation, however, presents unique challenges. Unlike generics, achieving complete similarity with reference products is complex due to inherent heterogeneity of biological molecules. Regulatory prerequisites necessitate rigorous comparative testing, thus calling for high-level of...
Discover more insightsThe Biomet sector is at the forefront of innovation in the medical devices industry, with companies continually innovating to manufacture high-quality, patient-centric devices. Advancements in biomedical engineering and materials technology have enabled the production of devices that are more biocompatible and effective. Novel technologies such as 3D printing and AI...
Discover more insightsBiosimilars are biologic medical products highly similar to another already approved biological medicine. They aim to achieve the same therapeutic effect, often at less cost than their reference innovator drugs. As large pharmaceutical patents expire, biosimilars pave the way for competitive drug pricing, increasing market accessibility and affordability.
Discover more insightsThe biosimilars market is witnessing a steady growth globally due to factors such as increasing healthcare expenditures, population aging, increasing prevalence of chronic diseases, and advancements in biologic therapies. However, the market also continues to face challenges, chief among them being regulatory hurdles, patent disputes and the need for substantial...
Discover more insightsThe global biosimilars industry presents a promising growth avenue. The market is fueled by a variety of factors, such as increased acceptance of biosimilar products, expiration of originator biologics patents, burgeoning chronic disease prevalence, and pressure on healthcare systems to cut costs. These factors set the stage for a broad...
Discover more insightsBiomet, as a key player in the orthopedics industry, has established a solid foothold in the market, attributed largely to its advanced product portfolio. Specializing in reconstructive products, sports medicine, trauma, spine, craniomaxillofacial and thoracic products, Biomet is widely recognized for its quality offerings in these sectors. The company's systemic...
Discover more insightsThe biostimulants sector has demonstrated robust growth in recent years, driven by an increased global focus on sustainable farming solutions and food security. These products, aimed at enhancing crop yield and quality, have seen a surge in demand, particularly in progressive agri-markets. Despite the ongoing market dynamism, it's crucial to...
Discover more insightsThe landscape of clinical trials related to biosimilars signifies an expanding frontier in the pharmaceutical industry. These are tests conducted on biopharmaceutical drugs designed to have active properties similar to ones that have already been licensed. They offer a potential pathway to introduce more cost-effective therapies, as biosimilars are typically...
Discover more insightsAs governmental regulations regarding biosimilar drug approvals have changed, there has been a consequential shift in the biosimilars market landscape. Collaborations between leading pharmaceutical firms and biotechnology companies are escalating, bolstering the sector's research and development capabilities. These alliances not only provide financial support but also share potentially replicable know-how,...
Discover more insightsIn the global pharmaceutical landscape, biosimulation holds a prominent role due to its application in drug discovery. Utilized as a scientific approach to predict responses to drugs and disease progress within human cells, it facilitates decision-making processes and accelerates product development trajectories. Enhanced predictability reduces the time and cost associated...
Discover more insightsThe COVID-19 pandemic has undeniably influenced various industries, and the biosimilars market is no exception. Faced with unprecedented challenges, the market has shown resilience. Despite initial disruption due to lockdown restrictions affecting production and distribution, quick rebound has been noted due to increased cost-consciousness and demand for affordable healthcare in...
Discover more insightsAs tertiary products emerging out of medical biotechnology, biosimilars face a rigorous and meticulous regulatory procedure. With their complex molecular structure, the approval process extends beyond a simple scrutiny of bioequivalence, necessitating intensive comparative studies on safety, quality, and efficacy against the innovator product. The ensuing competitive market tension drives...
Discover more insightsThe Biosimilar market, a sub-segment of the broader pharmaceutical industry, is currently gaining momentum due to increased recognition and acceptance. The market's growth is primarily fueled by patent expirations of notable biologics, resulting in the surge of more affordable biosimilar options. Cost-effectiveness, coupled with the assurance of quality and safety...
Discover more insightsAs biologic medicines near patent expiration, biosimilars - cheaper, highly similar versions - have become a topic of interest for many investors. The global market is projected to reach $35.7 billion by 2025, spurred by increasing healthcare cost pressures and an aging population with escalating chronic disease prevalence. While North...
Discover more insightsThe biosimilar sector, characterised by pharmaceuticals which are nearly identical copies of original brand medications, is experiencing an increasing growth pace. This uptick can be attributed to patent expiry of multiple branded biologics, creating a window for their biosimilar counterparts. Additionally, an influx of strategic and manufacturing partnerships within the...
Discover more insightsIncorporation of technology with biology has observed a major uptick, introducing the market to the phenomenon of biosimulation. A robust computational technique, biosimulation aids in the simulation of biological processes, thereby refining function and performance of pharmaceutical research. Unprecedented advancements in drug development, growing acceptance of quantitative systems pharmacology (QSP)...
Discover more insightsBiorationals, a derived segment of the overall biopesticides market, is shaping agribusiness with its potential for growth. This rise can be ascribed to market drivers such as rising global food demand, growing awareness about environmental sustainability, and stringent regulatory pressure on chemical pesticides. These agricultural substances, inherently less toxic than...
Discover more insightsThe biostimulants market experiences considerable expansion due to a convergence of factors. Stricter environmental regulations encourage the development and use of eco-friendly products, which positions biostimulants as an attractive solution. The drive for sustainable agriculture also attributes to this growth. The increasing global population necessitates improved crop yield and quality,...
Discover more insightsThe biosimilars sector is experiencing significant change: propelled by the expiry of patents on biologic drugs, this has led to competitive pressures, prompting increased activity within the biosimilars market. This surge in dynamism extends to a larger market share and increased profitability potential. Moreover, cost-effectiveness in comparison to biologics has...
Discover more insights